Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
01 1Bachem AG
02 4Debiopharm Research & Manufacturing SA
03 1PolyPeptide Laboratories Private Limited
04 1Synergy Health AST, Inc
05 3Synergy Health AST, LLC
01 1Triptorelin
02 2Triptorelin Pamoate
03 3Triptorelin pamoate
04 1triptorelin
05 3triptorelin pamoate
01 6Switzerland
02 4U.S.A
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 55463-0006
Start Marketing Date : 2006-06-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62788-288
Start Marketing Date : 2001-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (11.25mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-437
Start Marketing Date : 2010-10-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-715
Start Marketing Date : 2000-06-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (3.75mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-956
Start Marketing Date : 2017-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 59149-006
Start Marketing Date : 2023-02-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (500g/500g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71161-103
Start Marketing Date : 2000-06-15
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-104
Start Marketing Date : 2001-06-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (11.25mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-105
Start Marketing Date : 2010-03-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-106
Start Marketing Date : 2017-09-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
A Watson Brand of Triptorelin Embonate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Watson Brand of Triptorelin Embonate, including repackagers and relabelers. The FDA regulates Watson Brand of Triptorelin Embonate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Watson Brand of Triptorelin Embonate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Watson Brand of Triptorelin Embonate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Watson Brand of Triptorelin Embonate supplier is an individual or a company that provides Watson Brand of Triptorelin Embonate active pharmaceutical ingredient (API) or Watson Brand of Triptorelin Embonate finished formulations upon request. The Watson Brand of Triptorelin Embonate suppliers may include Watson Brand of Triptorelin Embonate API manufacturers, exporters, distributors and traders.
click here to find a list of Watson Brand of Triptorelin Embonate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Watson Brand of Triptorelin Embonate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Watson Brand of Triptorelin Embonate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Watson Brand of Triptorelin Embonate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Watson Brand of Triptorelin Embonate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Watson Brand of Triptorelin Embonate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Watson Brand of Triptorelin Embonate suppliers with NDC on PharmaCompass.
We have 4 companies offering Watson Brand of Triptorelin Embonate
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
